Try our beta test site
38 studies found for:    Open Studies | "Essential Thrombocythemia"
Show Display Options
Rank Status Study
1 Not yet recruiting Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia
Conditions: MPN;   Essential Thrombocythemia
Interventions: Other: Aspirin therapy interruption;   Other: Usual treatment by aspirin 100 mg/d in the active comparator arm;   Other: No interruption of aspirin in the Observational arm;   Drug: Hydroxyurea treatment (HU)
2 Recruiting Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
Conditions: Myelofibrosis;   Essential Thrombocythemia
Intervention:
3 Recruiting Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Interventions: Drug: RG7388;   Drug: Pegasys
4 Recruiting The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
Conditions: Polycythemia Vera (PV);   Essential Thrombocythemia (ET)
Interventions: Drug: Ruxolitinib;   Drug: BAT
5 Recruiting The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
Condition: Essential Thrombocythemia
Interventions: Drug: Anagrelide;   Drug: Ruxolitinib (JAKAVI®);   Drug: IFNα/ PegIFNα
6 Recruiting Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes
Conditions: Polycythemia Vera;   Essential Thrombocythemia;   Myelofibrosis
Intervention:
7 Recruiting Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
Conditions: Primary Myelofibrosis;   Post Essential Thrombocythemia-myelofibrosis;   Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
8 Recruiting Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Procedure: Blood specimen
9 Recruiting Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure
Conditions: Polycythemia Vera;   Thrombocythemia, Essential
Intervention: Drug: No cytoreductive vs cytoreductive drugs
10 Recruiting Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease
Condition: Myelofibrosis
Interventions: Drug: Idelalisib;   Drug: Ruxolitinib
11 Recruiting Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Condition: Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Glasdegib (PF-04449913);   Drug: Placebo
12 Not yet recruiting Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Biological: RNA sample of total leukocytes before start of treatment
13 Recruiting Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Conditions: Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Primary Myelofibrosis
Interventions: Biological: Durvalumab;   Other: Laboratory Biomarker Analysis
14 Recruiting Phase 2 LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Condition: Leukemia
Interventions: Drug: LCL-161;   Behavioral: Questionnaires;   Other: Phone Calls
15 Recruiting Familial Myeloproliferative Disorders
Conditions: Polycythemia Vera;   Essential Thrombocythemia;   Idiopathic Myelofibrosis
Intervention:
16 Recruiting Myeloproliferative Neoplastic Diseases Observatory From Brest
Conditions: Polycythemia Vera;   Essential Thrombocythemia;   Primary Myelofibrosis
Intervention:
17 Recruiting Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.
Conditions: Primary Myelofibrosis (PMF);   Post-Polycythemia Vera-Myelofibrosis (PPV-MF);   Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
Intervention: Drug: ruxolitinib
18 Recruiting Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
Condition: Myelofibrosis
Intervention: Drug: Ruxolitinib
19 Recruiting Study of Nivolumab in Patients With Myelofibrosis
Condition: Myeloproliferative Diseases
Interventions: Drug: Nivolumab;   Behavioral: Questionnaire;   Behavioral: Phone Call
20 Recruiting Research Tissue Bank
Conditions: Myelofibrosis;   Idiopathic Myelofibrosis;   Essential Thrombocythemia;   Polycythemia Vera
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-38) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.